Tirzepatide 3-month results: what the studies actually show
Quick answer
The video documents an apparent 3-month outcome on compounded tirzepatide, a GIP/GLP-1 dual agonist shown in the SURMOUNT-1 trial to produce significant weight reduction, though 12-week results represent an early titration phase for most patients. Compounded tirzepatide is not FDA-approved and is not considered equivalent to brand-name Zepbound or Mounjaro. No clinical metrics, dosing information, or adverse event disclosure are provided in the video.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @christine.york2 actually say?
Honestly? Not much. The transcript is: "Check this out. Okay. I look good. Okay. On the street and I got my swag on. Okay. Get the." That's it. There are no dosing claims, no mechanism explanations, no before-and-after stats. The video's substance lives entirely in the hashtags: #tirzepatidecompound, #tirzepatideweightloss, #zepbound, #glp1sideeffects. The implicit claim being made here is visual. She's saying she lost weight over three months, she looks good, and tirzepatide is the reason. Whether that's accurate depends entirely on context we don't have.
That framing matters. When someone pairs a confident "I look good" with a compounded tirzepatide hashtag and a 3-month timeline, the audience reads a testimonial even if none is technically spoken. That's how health content works on TikTok, and it's worth being honest about that.
Does the science back this up?
The general premise, that tirzepatide can produce meaningful weight loss in roughly three months, is well-supported. But "I look good" is not a clinical outcome, and compounded tirzepatide is not the same product as brand-name Zepbound or Mounjaro.
The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that tirzepatide at 15 mg weekly produced an average 22.5% reduction in body weight over 72 weeks in adults with obesity. At 12 weeks, weight loss was already statistically significant but far below the endpoint figures. A 3-month window is real but early. Most participants in SURMOUNT-1 were still titrating doses at that point.
Separately, the FDA has not approved compounded tirzepatide as equivalent to Zepbound. The agency has stated explicitly that compounded drugs are not FDA-approved and may differ in safety and efficacy. Using the #tirzepatidecompound hashtag alongside #zepbound in the same post blurs that line in a way patients should notice.
What did they get wrong (or right)?
Credit where it's due: she didn't make any bogus mechanistic claims, didn't recommend a dose, didn't say tirzepatide "cures" anything. In the world of GLP-1 TikTok, that's actually a low bar that a lot of creators fail to clear, and she clears it.
What's missing is any acknowledgment of side effects, which is notable given that #glp1sideeffects is literally one of her own hashtags. The SURMOUNT-1 trial reported that 82.7% of participants on tirzepatide experienced gastrointestinal adverse events, including nausea, diarrhea, and vomiting. These aren't rare edge cases. For a video positioned as a 3-month results update, skipping that entirely is a real gap.
The bigger issue is the compounded tirzepatide framing. Compounded versions are produced under different manufacturing conditions, may use different salt forms, and are not subject to the same FDA review. Stacking that next to #zepbound implies equivalency. It doesn't exist.
What should you actually know?
Three months on tirzepatide is a starting point, not a finish line, and results vary significantly based on dose, adherence, diet, and individual metabolic response. The visual confidence in this video is real, but it's a sample size of one.
If you're considering compounded tirzepatide specifically, the FDA issued a statement in 2024 clarifying that compounded tirzepatide is not the same as Zepbound or Mounjaro and that patients should be aware of the distinction. The agency also noted concerns about compounded versions using tirzepatide base rather than tirzepatide monohydrate, the form used in approved products.
GLP-1 medications require medical supervision, titration protocols, and ongoing monitoring. A TikTok confidence check is not a treatment plan. If a video makes you want to start or switch a medication, that conversation belongs with a licensed provider who has access to your full medical history, not a comment section.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Tirzepatide 3-month results: what the studies actually show, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
The video documents an apparent 3-month outcome on compounded tirzepatide, a GIP/GLP-1 dual agonist shown in the SURMOUNT-1 trial to produce significant weight reduction, though 12-week results represent an early titration phase for most patients.
FormBlends verdict
The video documents an apparent 3-month outcome on compounded tirzepatide, a GIP/GLP-1 dual agonist shown in the SURMOUNT-1 trial to produce significant weight reduction, though 12-week results represent an early titration phase for most patients. Compounded tirzepatide is not FDA-approved and is not considered equivalent to brand-name Zepbound or Mounjaro. No clinical metrics, dosing information, or adverse event disclosure are provided in the video.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video documents an apparent 3-month outcome on compounded tirzepatide, a GIP/GLP-1 dual agonist shown in the SURMOUNT-1 trial to produce significant weight reduction, though 12-week results represent an early titration phase for most patients. Compounded tirzepatide is not FDA-approved and is not considered equivalent to brand-name Zepbound or Mounjaro. No clinical metrics, dosing information, or adverse event disclosure are provided in the video.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found tirzepatide 15 mg produced 22.5% average body weight reduction over 72 weeks, but 12-week results are early in the titration curve.
- The FDA has not approved compounded tirzepatide and has stated it is not equivalent to brand-name Zepbound or Mounjaro, including concerns about different salt forms used in some compounded versions.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found tirzepatide 15 mg produced 22.5% average body weight reduction over 72 weeks, but 12-week results are early in the titration curve.
- The FDA has not approved compounded tirzepatide and has stated it is not equivalent to brand-name Zepbound or Mounjaro, including concerns about different salt forms used in some compounded versions.
- 82.7% of tirzepatide participants in SURMOUNT-1 reported gastrointestinal side effects including nausea, diarrhea, and vomiting. Three-month highlight reels rarely include this context.
- Individual weight loss results at 3 months vary significantly based on starting dose, titration schedule, dietary changes, and individual metabolic factors. One person's results are not a prediction.
- Compounded tirzepatide exists because of FDA drug shortage designations, but the FDA removed tirzepatide from its shortage list in 2024, which affects the legal basis for compounding going forward.
- GLP-1 and GIP agonists require a prescribing provider, regular monitoring, and a titration protocol. Social media results posts are not a substitute for a clinical evaluation.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Christine 🌺 · TikTok creator
9.9K views on this video
3 month weight loss results! #tirzepatideweightloss #tirzepatidecompound #glp1sideeffects #zepbound #wegovy #skinnytheory #injectionsite #weightloss #weightlossresults #ww
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Christine 🌺, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.